Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Pancreatic Cancer Resectable × nimotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 7 Esophageal Neoplasms 4 Pancreatic Neoplasms 3 Esophageal Squamous Cell Carcinoma 2 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Pancreatic Cancer Resectable 1 Neoplasm Metastasis 1 Head and Neck Neoplasms 1 HCC 1

Interventions

nimotuzumab 1 Antineoplastic Agents 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06722911 2024-12-09

Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

Zhejiang Provincial People's Hospital

Phase 2 Recruiting

Gastrointestinal

Pancreatic Cancer Resectable

Data powered by HemOnc (CC BY 4.0) Colophon ⚡